MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Rigel Pharmaceuticals Operating Cash Flow 2011-2026 | RIGL
Annual Operating Cash Flow Rigel Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.5 M | -5.74 M | -73.8 M | 5.88 M | -52.2 M | -41.5 M | -58.8 M | -77.6 M | -75.9 M | -23.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.5 M | -77.6 M | -37.2 M |
Quarterly Operating Cash Flow Rigel Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -893 K | - | - | -5.01 M | - | - | -4.07 M | - | -51.8 M | - | -25.6 M | - | 25 M | - | -20 M | - | -36.6 M | -17.1 M | -3.09 M | - | -31.9 M | -17.2 M | -569 K | - | -70.5 M | -50.4 M | -23.4 M | - | -57.8 M | -40.2 M | -20.8 M | - | -63.4 M | -40.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25 M | -70.5 M | -26.5 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
45.3 M | $ 20.15 | -2.68 % | $ 2.54 B |  USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.82 | -3.48 % | $ 4.47 M |  China |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
181 M | $ 8.52 | -2.46 % | $ 1.39 B | Britain |
 |
Corvus Pharmaceuticals
CRVS
|
-23.9 M | $ 17.75 | -0.79 % | $ 852 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Certara
CERT
|
96.3 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-25.6 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-49.4 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 24.0 | 0.5 % | $ 2.93 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-224 M | $ 3.19 | -4.64 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-373 M | $ 28.78 | -1.44 % | $ 1.67 B | USA |
 |
Champions Oncology
CSBR
|
7.39 M | $ 6.0 | -1.15 % | $ 82 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.67 | -3.42 % | $ 116 M | France |
 |
Alector
ALEC
|
-184 M | $ 2.11 | -4.75 % | $ 217 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-153 M | $ 15.68 | -2.4 % | $ 779 M | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-79.8 M | $ 4.17 | 0.24 % | $ 296 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
6.73 M | $ 14.27 | 2.44 % | $ 5.92 B |  Irlanda |